BOSTON, NOV. 13, 2025 – Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has been awarded the Deloitte Technology Fast 50 Rising Star award.
The Rising Star award is one of the five categories of the Technology Fast 50 program, which highlights the fastest-growing tech companies. The rising star winners are nominated by Deloitte and their sponsors to honor industry leaders with notable accomplishments and dedication to innovation. Lindus Health was chosen by Deloitte as a recipient of the award in the HealthTech & BioTech sector.
Kiren Asad, lead partner for the Deloitte UK Technology Fast 50 programme, said, “For nearly three decades, the Fast 50 has highlighted rapidly growing and innovative technology companies across the UK. And 2025 is no different with this year’s cohort having grown around 20 times on average over three years, showing that the UK tech scale-up sector is continuing to demonstrate remarkable resilience amidst global economic shifts.
This prestigious recognition reflects Lindus’ ongoing commitment to developing adaptive, innovative technology that fixes the broken Contract Research Organization (CRO) model through its all-in-one solution. The company drives this change through its AI-enabled approaches across the study lifecycle, and its in-house, proprietary, end-to-end trial delivery platform, CitrusTM, ultimately accelerating timelines while delivering high-quality clinical trials.
“We are honored to be among the leading tech businesses that have won this award and are proud to be recognized for our achievements in accelerating clinical research using technology,” said Meri Beckwith, Co-CEO of Lindus Health.
Lindus Health is the anti-CRO running radically faster, more reliable clinical trials for life science pioneers—bringing ground-breaking treatments to patients more quickly. By aligning incentives through fixed-price, milestone-based contracts, combining a world-class clinical operations team with a unique software platform, and leveraging access to over 40 million Electronic Health Records, Lindus Health delivers trials designed for speed, reliability, and impact.
The company removes the biggest bottleneck in healthcare—clinical trials—through end-to-end study execution powered by technology and forward-thinking approaches to clinical operations. Lindus Health works with leading biotech, medical device, diagnostics, and consumer health companies to accelerate the development of innovative therapies and products. Its impact has been recognized with prestigious accolades, including the Fierce Biotech CRO Awards for Outstanding Patient Recruitment and Retention and inclusion in the PM360 Elite 100.
To date, Lindus Health has delivered trials across the US, UK, and Europe in conditions ranging from diabetes and asthma to major depressive disorder, hypertension, and chronic fatigue syndrome. The company has raised over $80M from investors including Balderton, Peter Thiel, Creandum, Firstminute Capital, and Seedcamp.
In this press release references to “Deloitte” are references to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”) a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms.
Deloitte LLP is a subsidiary of Deloitte NSE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Jodi Perkins
All-in-One CRO Solution Lindus Health Welcomes Heather Davis as Vice President of US Clinical Operations
Heather Davis joins the executive team, bringing 30 years of experience to continue expanding Lindus Health's footprint in North America.
